• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Immune Responses to Enzymes Replacement Therapies: Role of Immune Tolerance Induction

 

Meeting Information
 
Immune Responses to Enzymes Replacement Therapies: Role of Immune Tolerance Induction
The FDA in co-sponsorship with the National Organization for Rare Disorders (NORD) is announcing a 1-day public workshop. The workshop will provide a forum to discuss the role of immune tolerance induction in patients receiving replacement biological products.   
 
Date:                              June 9, 2014
 
Time:                              8:00 am to 5:00 pm
 
Location:                        FDA White Oak Campus
                                        Bldg. 31, Great Room 1503
                                        Silver Spring, MD 20993                                               
 
                                        (Information about arrival to FDA’s White Oak campus)
 
 
Registration:                 There is no fee to attend the public workshop, but advanced online registration is recommended.  Onsite registration is available on the day of the event but  advanced registration is preferred. To register online, please visit  https://events.rarediseases.org/?page_id=4&ee=13
 
The Workshop will also be available via webcast providing both audio and video broadcasting:  https://collaboration.fda.gov/immuneresponse/.
Final agenda and slides available at the registration site:  https://events.rarediseases.org/?ee=13
 
More Information
Contact:                          Maureen Dewey
                                        Tel: 301-796-0845
                                        Fax: 301-796-9905
                                        Email: Maureen.dewey@fda.hhs.gov
 
Meeting Information
 
·         Federal Register Notice